EMAIL THIS PAGE TO A FRIEND

Cancer letters

FOXC2 promotes chemoresistance in nasopharyngeal carcinomas via induction of epithelial mesenchymal transition.


PMID 25896630

Abstract

Paclitaxel (Taxol) is currently used as the front-line chemotherapeutic drug for many types of human cancers. However, the emergence of drug resistance has been a major obstacle to the effective treatment of cancers in clinical settings. The transcription factor Forkhead box protein C2 (FOXC2) was recently demonstrated to activate the epithelial-mesenchymal transition (EMT). In this article, we present a novel role of FOXC2 in regulating chemoresistance of nasopharyngeal carcinoma (NPC) through the EMT. Using an EMT PCR array based on the screening of 84 genes, the expression of FOXC2 was notably upregulated in paclitaxel-resistant NPC cells (CNE2/t). We observed that the paclitaxel-resistant cells exhibited characteristic EMT phenotypes. The silencing of FOXC2 expression in the resistant cells can reverse the EMT molecular markers and chemoresistant phenotypes, such as cellular morphology, proliferation and anoikis. In an NPC xenograft mouse model, the downregulation of FOXC2 expression in the resistant NPC cells increased their sensitivity to paclitaxel treatment, resulting in reduced tumor growth. Taken together, our results suggest that FOXC2-mediated EMT may be an alternative mechanism through which cancer cells can initiate and maintain drug resistance. Thus, targeting FOXC2 may provide a novel strategy for overcoming chemoresistance in NPC therapy.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB4500002
Anti-CDH2, C-Terminal antibody produced in rabbit, affinity isolated antibody
AV31703
Anti-FOXC2 (AB1) antibody produced in rabbit, IgG fraction of antiserum
AV32307
Anti-FOXC2 (AB2) antibody produced in rabbit, IgG fraction of antiserum
SAB2500411
Anti-FOXC2 antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB1412035 ANTI-FOXC2 antibody produced in mouse, clone 3H3, ascites fluid, buffered aqueous solution
SAB1412342
ANTI-FOXC2 antibody produced in mouse, clone 1A8, purified immunoglobulin, buffered aqueous solution
SAB1412343
ANTI-FOXC2 antibody produced in mouse, clone 3H5, purified immunoglobulin, buffered aqueous solution
SAB1412344
ANTI-FOXC2 antibody produced in mouse, clone 3E6, purified immunoglobulin, buffered aqueous solution
SAB1412345
ANTI-FOXC2 antibody produced in mouse, clone 4A5, purified immunoglobulin, buffered aqueous solution
SAB1412346
ANTI-FOXC2 antibody produced in mouse, clone 4A3, purified immunoglobulin, buffered aqueous solution
SAB1412479
ANTI-FOXC2 antibody produced in mouse, clone 1D4, purified immunoglobulin, buffered aqueous solution
F1054
Anti-FOXC2 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB2106499
Anti-FOXC2 antibody produced in rabbit, affinity isolated antibody
WH0002303M2
Monoclonal Anti-FOXC2 antibody produced in mouse, clone 2H3, purified immunoglobulin, buffered aqueous solution
SAB1403826
Monoclonal Anti-FOXC2, (C-terminal) antibody produced in mouse, clone 4B3, purified immunoglobulin, buffered aqueous solution